Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Consolidation in High-Risk Ph- ALL
NCT03523429Phase 2Terminated
- Sponsor
- Fundación PETHEMA
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Fundación PETHEMA. Started Jun 2018; status: terminated.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03523429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523429.